✦ LIBER ✦

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

✍ Scribed by Alasdair J Coles; Cary L Twyman; Douglas L Arnold; Jeffrey A Cohen; Christian Confavreux; Edward J Fox; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Howard L Weiner; Tamara Miller; Elizabeth Fisher; Rupert Sandbrink; Stephen L Lake; David H Margolin; Pedro Oyuela; Michael A Panzara; D Alastair S Compston

Book ID: 118553734
Publisher: The Lancet
Year: 2012
Tongue: English
Weight: 326 KB
Volume: 380
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(12)61768-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Alemtuzumab versus interferon beta 1a as

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

✍ Jeffrey A Cohen; Alasdair J Coles; Douglas L Arnold; Christian Confavreux; Edwar 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 334 KB

Simvastatin as add-on therapy to interfe

Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial

✍ Per Soelberg Sorensen; Jan Lycke; Juha-Pekka Erälinna; Astrid Edland; Xingchen W 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 349 KB

Effect of laquinimod on MRI-monitored di

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

✍ G Comi; A Pulizzi; M Rovaris; O Abramsky; T Arbizu; A Boiko; R Gold; E Havrdova; 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 143 KB

Efficacy of vitamin D3 as add-on therapy

Efficacy of vitamin D3 as add-on therapy in patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon beta-1a: A Phase II, multicenter, double-blind, randomized, placebo-controlled trial

✍ Joost Smolders; Raymond Hupperts; Frederik Barkhof; Luigi M.E. Grimaldi; Trygve 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 355 KB

Pridopidine for the treatment of motor f

Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial

✍ Justo Garcia de Yebenes; Bernhard Landwehrmeyer; Ferdinando Squitieri; Ralf Reil 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 113 KB

Pridopidine for the treatment of motor f

Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial

✍ Justo Garcia de Yebenes; Bernhard Landwehrmeyer; Ferdinando Squitieri; Ralf Reil 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 113 KB